Kristin Mulready, MS, GCEC
Kristin Mulready, MS, GCEC, is leading our strategic program management capability on a consulting basis. She has over 25 years of biopharma experience with expertise in executional strategy, business operations, and scientific program leadership. She has established and transformed enabling program, alliance, portfolio, and supportive capabilities/teams in small, mid‐sized, and large organizations during periods of growth, maintenance, and downsizing. In the course of that work, she has driven improved and integrated governance and supportive business operations/systems including diagnostics, scientific feasibility, defining metrics (KPIs), PM/AM core capabilities, IT capability/tools, HR practices, optimized modes of communication, mentorship, while ensuring fitting team representation.
Kristin is skilled in facilitating efficient decision-making, aligning and prioritizing scientific/clinical goals, addressing risks/conflicts candidly, transparent communication, and adaptive change management strategies. She is also a certified Executive/Leadership Coach.
Prior to launching her consulting business, she was Vice President of Portfolio, Program, and Alliance functions at BlueRock Therapeutics and Acer Therapeutics. She also led those functions at Mersana Therapeutics and held strategic program and alliance management roles at Takeda Pharmaceuticals and ImmunoGen, Inc. Early in her career, Kristin was a Discovery Cell Biologist. She has been responsible for over 40 programs spanning Research through Commercialized stage, Oncology, rare disease, GI, Neurology, Cardiac indications, ADCs, biologics, small molecule, cell & gene therapy modalities as well as proprietary and partnered programs in venture-backed, pre-IPO, public, and private wholly-owned, local and global organizations.
Kristin holds a Master's Degree in Management from Lasell College, a Graduate Certificate in Executive Coaching from William James College, and an undergraduate degree in Biology from Colby-Sawyer College.
Kristin was introduced to Mitera Biosciences through Spannerwerks, Inc.